Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center
Substantial improvements in lung function and reductions in HCRU were observed after treatment with ELX/TEZ/IVA in the Verona CF Center. Results contribute to the growing evidence of country-specific real-world data on the positive impact of ELX/TEZ/IVA.
Authors
- Teja Thorat (ORCID: https://orcid.org/0000-0003-2856-752X)
- Emily Pintani
- Marco Cipolli (ORCID: https://orcid.org/0000-0001-5652-7248)
- Andrew J Fratoni (ORCID: https://orcid.org/0000-0002-5874-5174)
- G. Vega-Hernández
- Francesca Lucca (ORCID: https://orcid.org/0000-0002-5294-9301)
- Pia Clara Pafundi (ORCID: https://orcid.org/0000-0002-0310-3529)
- Ilaria Meneghelli
- Daniela Paola Roggeri (ORCID: https://orcid.org/0000-0003-4676-4164)
- Carlotta Rossi (ORCID: https://orcid.org/0000-0001-9133-971X)
- Alessandro Roggeri (ORCID: https://orcid.org/0000-0002-9664-0306)
Institutions
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Northeast Radio Observatory Corporation (US)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1007/s41030-025-00334-x
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00